Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Can 89Zr-atezolizumab PET Scan Identify Patients With Metastatic Invasive Lobular Breast Cancer Who Will Respond to Chemotherapy-immune Checkpoint Inhibition?

NCT04222426 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT04222426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04222426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Can 89Zr-atezolizumab PET Scan Identify Patients With Metastatic Invasive Lobular Breast Cancer Who Will Respond to Chemotherapy-immune Checkpoint Inhibition?
Lead sponsor
University Medical Center Groningen
Phase
Not applicable
Overall status
Terminated
Start date
December 18, 2019
Completion date
May 1, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lobular metastatic breast cancer